Patent Assignment
Reel/Frame 029825/0070
Change of Name
Recorded: 2013-02-18
Pages: 7
Assignor
ABBOTT BIOTHERAPEUTICS CORP
Executed: 2012-11-28
Assignee
ABBVIE BIOTHERAPEUTICS INC.
1500 SEAPORT BLVD, REDWOOD CITY, CALIFORNIA, 94063
Covered Properties
(30)
Bispecific Antibody Heterodimers
Patent:
5,932,448 →
Application:
07/801,798 →
Mutated Nonactivating IGG2 Domains and Anti-CD3 Antibodies Incorporating the Same
Patent:
5,834,597 →
Application:
08/656,586 →
Method of Preventing Acute Rejection Following Solid Organ Transplantation
Patent:
6,013,256 →
Application:
08/934,841 →
Methods of Diagnosing Breast Cancer
Patent:
6,762,020 →
Application:
09/642,034 →
Novel Methods of Diagnosing Breast Cancer, Compositions, and Methods of Screening for Breast Cancer Modulators
Patent:
6,649,342 →
Application:
09/657,960 →
Methods of Diagnosing Breast Cancer
Patent:
6,780,586 →
Application:
09/702,216 →
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Stable Lyophilized Pharmaceutical Formulation of Igg Antibodies
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
Immunoglobulin Display Vectors
Method of Screening Complex Protein Libraries to Identify Altered Properties
Application:
12/340,199 →
Publication:
US 2013/0338038
Methods of Screening Complex Protein Libraries to Identify Altered Properties
Therapeutic Use of Anti-CS1 Antibodies
Stable Lyophilized Pharmaceutical Formulation of Igg Antibodies
Mammalian Cell-Based Immunoglobulin Display Libraries
Alteration of Fc-Fusion Protein Serum Half-Lives by Mutagenesis
Compositions Against Cancer Antigen Liv-1 and Uses Thereof
Chimeric and Humanized Antibodies to ALPHA5BETA1 Integrin That Modulate Angiogenesis
CTLA4 Proteins and Their Uses
Immunoglobulin Display Vectors
Use of Anti-CS1 Antibodies for Treatment of Rare Lymphomas
Stable Aqueous Pharmaceutical Formulations of Daclizumab Antibodies
ANTI-TNF-a ANTIBODIES AND THEIR USES
Application:
13/264,983 →
Publication:
US 2012/0135005
Dac Hyp Compositions and Methods
Application:
13/481,081 →
Publication:
US 2012/0301429
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Nov 12, 1996
From: TSO, J. YUN; COLE, MICHAEL S.
To: PROTEIN DESIGN LABS, INCORPORATED
Reel/Frame 008216/0328 →
Assignment of Assignor's Interest
Nov 12, 1996
From: ANASETTI, CLAUDIO
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 008217/0886 →
Assignment of Assignor's Interest
Dec 10, 2003
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014787/0675 →
Assignment of Assignor's Interest
Dec 22, 2003
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 014837/0794 →
Assignment of Assignor's Interest
Nov 19, 2004
From: RAMAKRISHNAN, VANITHA; POWERS, DAVID; JOHNSON, DALE E.; JEFFRY, URSULA
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 015376/0971 →
Assignment of Assignor's Interest
Mar 16, 2005
From: HINTON, PAUL R.; TSURUSHITA, NAOYA
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 015782/0651 →
Assignment of Assignor's Interest
Mar 30, 2005
From: RAMAKRISHNAN, VANITHA; POWERS, DAVID; JOHNSON, DALE; JEFFRY, URSULA
To: PROTEIN DESIGN LABS, INC
Reel/Frame 015840/0213 →
Change of Name
Mar 27, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017370/0001 →
Change of Name
Apr 17, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017480/0242 →
Merger
Apr 17, 2006
From: EOS BIOTECHNOLOGY, INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017480/0201 →
Change of Name
May 19, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017636/0787 →
Change of Name
May 22, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017655/0436 →
Assignment of Assignor's Interest
Feb 25, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022310/0517 →
Assignment of Assignor's Interest
Mar 4, 2009
From: DUBRIDGE, ROBERT; RHODES, SUSAN; ZHANG, WENGE
To: PDL BIOPHARMA, INC.
Reel/Frame 022345/0645 →
Assignment of Assignor's Interest
Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0269 →
Assignment of Assignor's Interest
Mar 4, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022343/0256 →
Assignment of Assignor's Interest
Mar 12, 2009
From: DUBRIDGE, ROBERT; POWERS, DAVID
To: PDL BIOPHARMA, INC.
Reel/Frame 022387/0515 →
Assignment of Assignor's Interest
Mar 12, 2009
From: DUBRIDGE, ROBERT; POWERS, DAVID
To: PDL BIOPHARMA, INC.
Reel/Frame 022387/0478 →
Assignment of Assignor's Interest
Apr 13, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022537/0440 →
Assignment of Assignor's Interest
Apr 13, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 022537/0360 →
Assignment of Assignor's Interest
Sep 18, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023245/0973 →
Assignment of Assignor's Interest
Dec 15, 2009
From: PDL BIOPHARMA, INC.
To: FACET BIOTECH CORPORATION
Reel/Frame 023649/0752 →
Change of Name
Nov 11, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP
Reel/Frame 025353/0698 →
Change of Name
Dec 7, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025445/0807 →
Change of Name
Dec 9, 2010
From: FACET BIOTECH CORPORATION
To: ABBOTT BIOTHERAPEUTICS CORP.
Reel/Frame 025483/0591 →